Paul Goldenheim, MD
This content is PDF only. Please click on the PDF icon to access.
To the Editor: Dr. Rossing's editorial (1), "Methylxanthines in 1989," raises some concerns as he concludes that:
although theophylline remains useful in a few clinical situations, it is no longer the mainstay in the treatment of airway obstruction. It seems likely that theophylline use will decline further as clinicians continue to adopt inhaled bronchodilators and anti-inflammatory drugs as first-line therapy.
I am concerned that Dr. Rossing arrives at these conclusions largely from observations in severe, acute asthma and extends these findings to asthma therapy in general. Acute attacks are a component of this disease; however, the therapeutic approach involves strategies
Goldenheim P. Methylxanthines. Ann Intern Med. ;112:74. doi: 10.7326/0003-4819-112-1-74_1
Download citation file:
Published: Ann Intern Med. 1990;112(1):74.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use